Table 1. Enrolled patient information.
| AA | C | |
| Patients enrolled | 145 | 82 |
| Male | 54 | 38 |
| Average age (s.d.) | 48.5 (7.97) | 44.3 (9.51) |
| Average weight1 (s.d.) | 198.6 (32.91) | 205.0 (39.76) |
| Female | 91 | 44 |
| Average age (s.d.) | 48.9 (42.1) | 46.0 (7.99) |
| Average weight1 (s.d.) | 185.2 (41.92) | 170.9 (56.18) |
| Il28B rs12979860 Genotype2 | CC 9 (8.4%) | 20 (33%) |
| TT 39 (36%) | 6 (10%) | |
| C/T 59 (55%) | 34 (57%) | |
| Infected with genotype 1a3 | 99 | 69 |
| 1b | 45 | 10 |
| Average years infected (max/min) | 22 (43/1) | 21 (47/3) |
| Average pre-therapy serum HCV IU/ml4 (s.d.) | 1,064,878 (1,377,098) | 1,599,894 (2,451,571) |
| Average ALT (s.d.) | 88 (62) | 103 (65) |
| Average fibrosis score (s.d.)5 | 2.0 (1.1) | 1.9 (0.9) |
| Mild fibrosis (0–2) | 104 | 56 |
| Advanced fibrosis (3–4) | 39 | 26 |
1
Weight is in US pounds.
2
Likelihood ratio = 24.72, p = 4.3×10−6. Il28B rs12979860 SNP genotypes were determined for 107 AA and 60 C.